AKODIO Trademark

Trademark Overview


On Monday, March 17, 2025, a trademark application was filed for AKODIO with the United States Patent and Trademark Office. The USPTO has given the AKODIO trademark a serial number of 99087526. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, April 21, 2026. This trademark is owned by Akodio Therapeutics, Inc.. The AKODIO trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Monoclonal antibodies and drug conjugates for the treatment of multiple Sclerosis, Alzheimer disease, stroke, traumatic brain injury, long COVID, postoperative cognitive decline, brain B-cell lymphoma, small vessel disease (CADACIL), adrenoleukodystrophy; biological products, namely, monoclonal antibodies for experimental purposes as part of medical treatment for multiple Sclerosis, Alzheimer disease, stroke, traumatic brain injury, long COVID, postoperative cognitive decline, brain B-cell lymphoma, small vessel disease (CADACIL), adrenoleukodystrophy

Medical probes; probes for medical imaging, namely, fluorescent and PET probes; medical devices for neuroimaging, neuro-diagnostics and neuro-monitoring
akodio

General Information


Serial Number99087526
Word MarkAKODIO
Filing DateMonday, March 17, 2025
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, April 21, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 21, 2026

Trademark Statements


Goods and ServicesMonoclonal antibodies and drug conjugates for the treatment of multiple Sclerosis, Alzheimer disease, stroke, traumatic brain injury, long COVID, postoperative cognitive decline, brain B-cell lymphoma, small vessel disease (CADACIL), adrenoleukodystrophy; biological products, namely, monoclonal antibodies for experimental purposes as part of medical treatment for multiple Sclerosis, Alzheimer disease, stroke, traumatic brain injury, long COVID, postoperative cognitive decline, brain B-cell lymphoma, small vessel disease (CADACIL), adrenoleukodystrophy
Goods and ServicesMedical probes; probes for medical imaging, namely, fluorescent and PET probes; medical devices for neuroimaging, neuro-diagnostics and neuro-monitoring

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 17, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateMonday, March 17, 2025
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAkodio Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94107
US

Party NameAkodio Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94107
US

Trademark Events


Event DateEvent Description
Monday, March 17, 2025NEW APPLICATION ENTERED
Monday, March 17, 2025APPLICATION FILING RECEIPT MAILED
Thursday, July 10, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 15, 2025ASSIGNED TO EXAMINER
Friday, August 22, 2025NON-FINAL ACTION WRITTEN
Friday, August 22, 2025NON-FINAL ACTION E-MAILED
Friday, August 22, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 24, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, November 24, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, February 20, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 20, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 20, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 17, 2026NON-FINAL ACTION WRITTEN
Tuesday, March 17, 2026NON-FINAL ACTION E-MAILED
Tuesday, March 17, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 25, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 25, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 25, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 26, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 15, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 21, 2026PUBLISHED FOR OPPOSITION
Tuesday, April 21, 2026OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED